Abstract
Pharmacokinetic/pharmacodynamic (PK/PD) analysis has proved to be very useful to establish rational dosage regimens of antimicrobial agents in human and veterinary medicine. Actually, PK/PD studies are included in the European Medicines Agency (EMA) guidelines for the evaluation of medicinal products. The PK/PD approach implies the use of in vitro, ex vivo, and in vivo models, as well as mathematical models to describe the relationship between the kinetics and the dynamic to determine the optimal dosing regimens of antimicrobials, but also to establish susceptibility breakpoints, and prevention of resistance. The final goal is to optimize therapy in order to maximize efficacy and minimize side effects and emergence of resistance. In this review, we revise the PK/PD principles and the models to investigate the relationship between the PK and the PD of antibiotics. Additionally, we highlight the outstanding role of the PK/PD analysis at different levels, from the development and evaluation of new antibiotics to the optimization of the dosage regimens of currently available drugs, both for human and animal use.
Funder
Hezkuntza, Hizkuntza Politika Eta Kultura Saila, Eusko Jaurlaritza
Euskal Herriko Unibertsitatea
Reference152 articles.
1. World Health Organization Model List of Essential Medicines, 21st List, 2019,2019
2. Antimicrobial Resistancehttps://www.who.int/health-topics/antimicrobial-resistance
3. The 2019 Who Aware Classification of Antibiotics for Evaluation and Monitoring of Use,2019
4. Global Action Plan on Antimicrobial Resistancehttps://www.who.int/antimicrobial-resistance/global-action-plan/en/
5. Preclinical Pharmacokinetic/Pharmacodynamic Studies and Clinical Trials in the Drug Development Process of EMA-Approved Antibacterial Agents: A Review
Cited by
59 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献